Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/79380
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis
Author: Kruger, Peter
Bailey, Michael
Bellomo, Rinaldo
Cooper, David James
Harward, Meg
Higgins, Alisa
Howe, Belinda
Jones, Darryl
Joyce, Chris
Kostner, Karam
McNeil, John James
Nichol, Alistair
Roberts, Michael S.
Syres, Gillian A.
Venkatesh, Bala
ANZ-STATInS Investigators-ANZICS Clinical Trials Group
Citation: American Journal of Respiratory and Critical Care Medicine, 2013; 187(7):743-750
Publisher: American Thoracic Society
Issue Date: 2013
ISSN: 1073-449X
School/Discipline: School of Medical Sciences
Statement of
Responsibility: 
Peter Kruger, Michael Bailey, Rinaldo Bellomo, David James Cooper, Meg Harward, Alisa Higgins, Belinda Howe, Darryl Jones, Chris Joyce, Karam Kostner, John McNeil, Alistair Nichol, Michael S. Roberts, Gillian Syres and Bala Venkatesh for the ANZ-STATInS Investigators-ANZICS Clinical Trials Group
Abstract: RATIONALE: Observational studies link statin therapy with improved outcomes in patients with severe sepsis. OBJECTIVES: To test whether atorvastatin therapy affects biologic and clinical outcomes in critically ill patients with severe sepsis. METHODS: Phase II, multicenter, prospective, randomized, doubleblind, placebo-controlled trial stratified by site and prior statin use. A cohort of 250 critically ill patients (123 statins, 127 placebo) with severe sepsis were administrated either atorvastatin (20mgdaily) or matched placebo. MEASUREMENTS AND MAIN RESULTS: There was no difference in IL-6 concentrations (primary end point) between the atorvastatin and placebo groups (P¼0.76) and no interaction between treatment group and time to suggest that the groups behaved differently over time (P ¼ 0.26). Baseline plasma IL-6 was lower among previous statin users (129 [87–191] vs. 244 [187–317] pg/ml; P ¼ 0.01). There was no difference in length of stay, change in Sequential Organ Failure Assessment scores or mortality at intensive care unit discharge, hospital discharge, 28- or 90-day (15% vs. 19%), or adverse effects betweenthetwogroups. Cholesterolwaslower in patients treatedwith atorvastatin (2.4 [0.07] vs. 2.6 [0.06] mmol/L; P ¼ 0.006). In the predefined group of 77 prior statin users, those randomized to placebo hada greater 28-day mortality(28%vs.5%;P¼0.01) compared with those who received atorvastatin. The difference was not statistically significant at 90 days (28% vs. 11%; P ¼ 0.06). CONCLUSIONS: Atorvastatin therapy in severe sepsis did not affect IL-6 levels. Prior statin use was associated with a lower baseline IL-6 concentration and continuation of atorvastatin in this cohort was associated with improved survival. Clinical trial registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12607000028404).
Keywords: Statin; 3-hydroxy-3-methylglutaryl CoA reductase inhibitor; sepsis; critical illness; mortality
Rights: Copyright © 2013 by the American Thoracic Society
RMID: 0020126539
DOI: 10.1164/rccm.201209-1718OC
Appears in Collections:Medical Sciences publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.